Spero Therapeutics, Inc.
HealthcareNASDAQ:SPRO · NASDAQ Global Select
+$0.15 today
Vol 0.62M · Avg 0.56M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
14.5%
avg -539.8%
ROIC
-0.0%
avg -242.8%
ROA
12.4%
avg -58.5%
Analysis
ROE is currently the strongest return metric at 14.5% versus its period average of -539.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Esther Rajavelu | CEO, President, CFO, Chief Business Officer, Treasurer & Director | $1.65M | — | 47 | $986,851.00 | 1.70% |
Timothy Keutzer | Chief Operating Officer | $1.23M | — | 58 | $742,506.00 | 1.28% |
John Raymond | Senior Vice President of Finance & Business Operations | — | — | — | $75,000.00 | 0.13% |
Sheila Finan | Senior VP & Controller | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
11
$568,328.13
Net Sentiment
$568,328.13
Net selling
Most Active
Rajavelu Esther
5 transactions
1–10 of 11
Analysis
Insiders reported 0 buys worth $0.00 and 11 sells worth $568,328.13 over the last 12 months. That adds up to net selling of $568,328.13. Rajavelu Esther was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +278.4% | +18.5% (10yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +278.4% over three years. Forward estimates point to Revenue at +18.5% (10yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
TuHURA Biosciences, Inc.
NASDAQ:HURA
$147.74M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBP
$102.67M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Actuate Therapeutics Inc
ACTU
$48.33M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Who manages SPRO?
Spero Therapeutics, Inc. (SPRO) lists 4 active executives. The top listed executive is Esther Rajavelu, CEO, President, CFO, Chief Business Officer, Treasurer & Director.
Are SPRO insiders buying or selling?
Recent insider activity shows net buying of $23.13M.
Explore More
Continue the stock analysis
Jump to another research area for this company.